Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan-Reference-Cited by-同舟云学术

Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan

Published:2015-05-07 Issue:5 Volume:170 Page:657-668
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chihara Dai¹²,Asano Naoko³,Ohmachi Ken⁴,Kinoshita Tomohiro⁵,Okamoto Masataka⁶,Maeda Yoshinobu⁷,Mizuno Ishikazu⁸,Matsue Kosei⁹,Uchida Toshiki¹⁰,Nagai Hirokazu¹¹,Nishikori Momoko¹²,Nakamura Shigeo³,Ogura Michinori¹³,Suzuki Ritsuro¹⁴

Affiliation:

1. Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston TX USA

2. Division of Epidemiology and Prevention; Aichi Cancer Centre Research Institute; Nagoya Japan

3. Department of Pathology and Clinical Laboratories; Nagoya University Graduate School of Medicine; Nagoya Japan

4. Department of Haematology and Oncology; Tokai University School of Medicine; Isehara Japan

5. Department of Haematology and Cell Therapy; Aichi Cancer Centre Hospital; Nagoya Japan

6. Department of Haematology and Medical Oncology; Fujita Health University School of Medicine; Toyoake Japan

7. Department of Haematology and Oncology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; Okayama Japan

8. Haematology Division; Department of Medicine; Hyogo Cancer Centre; Akashi Japan

9. Department of Haematology; Kameda Medical Centre; Kamogawa Japan

10. Department of Haematology and Oncology; Nagoya Daini Red Cross Hospital; Nagoya Japan

11. Department of Haematology; National Hospital Organization Nagoya Medical Centre; Nagoya Japan

12. Department of Haematology and Oncology; Kyoto University Graduate School of Medicine; Kyoto Japan

13. Department of Haematology and Laboratory Medicine; Suzuka National Hospital; Suzuka Japan

14. Department of HSCT Data Management and Biostatistics; Nagoya University Graduate School of Medicine; Nagoya Japan

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13486/fullpdf

Reference36 articles.

1. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study;Abrahamsson;Blood,2014

2. Using primary site as a predictor of survival in mantle cell lymphoma;Ambinder;Cancer,2013

3. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

4. Differences in incidence and trends of haematological malignancies in Japan and the United States;Chihara;British Journal of Haematology,2014

5. The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/− rituximab: results of a randomized phase II trial;Eve;Leukaemia & Lymphoma,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrasinusoidal bone marrow involvement in mantle cell lymphoma: a case series with review of the main differential diagnoses;Virchows Archiv;2024-08-06

2. A case of mantle cell lymphoma (MCL) detected with initial symptoms in the oral region;Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology;2024-08

3. Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score;Leukemia & Lymphoma;2023-06-01

4. Stem cell transplant for mantle cell lymphoma in Taiwan;Scientific Reports;2022-04-05

5. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial;Cancers;2021-12-31